Monday, February 25, 2019 Daily Archives

Danaher absorbing GE’s bioprocess biz in $21.4bn deal

by

Danaher Corporation will consolidate its position in the supplier space through the $21.4 billion acquisition of GE Healthcare’s biopharma division. The business will not be integrated with Pall. The deal, expected to be completed in the fourth quarter of 2019, will see Danaher Corporation buy the full BioPharma portion of GE Healthcare’s Life Sciences business for a cash purchase price of approximately $21.4 billion (€18.9 billion). The business, which pulls in about $3 billion in annual revenue, provides tools to…

February 25, 2019

Roche to buy gene therapy firm Spark for $4.3bn

by

The acquisition of Spark Therapeutics will add commercial product Luxturna to Roche’s portfolio, along with a pipeline of gene therapies. Swiss pharma firm Roche has announced today it is set to buy Spark Therapeutics for approximately $4.3 billion (€3.8 billion). “The merger agreement has been unanimously approved by the boards of Spark Therapeutics and Roche,†Roche spokesperson Simone Oeschger told BioProcess Insider. “Under the terms of the merger agreement, Roche will promptly commence a tender offer, to acquire all outstanding…

February 25, 2019